


Solubilization of Therapeutic Agents in Micellar Nanomedicines

Lela Vuković,[†] Antonett Madriaga,[†] Antonina Kuzmis,[‡] Amrita Banerjee,[‡] Alan Tang,[†] Kevin Tao,[‡] Neil Shah,^{†,‡} Petr Král,^{*,†,§} and Hayat Onyuksel^{*,‡,||}[†]Department of Chemistry, University of Illinois at Chicago, Chicago, Illinois 60607, United States[‡]Department of Biopharmaceutical Sciences, University of Illinois at Chicago, Chicago, Illinois 60612, United States[§]Department of Physics, University of Illinois at Chicago, Chicago, Illinois 60607, United States^{||}Department of Bioengineering, University of Illinois at Chicago, Chicago, Illinois 60607, United States

Supporting Information

ABSTRACT: We use atomistic molecular dynamics simulations to reveal the binding mechanisms of therapeutic agents in PEG-ylated micellar nanocarriers (SSM). In our experiments, SSM in buffer solutions can solubilize either ≈ 11 small bexarotene molecules or ≈ 6 (2 in low ionic strength buffer) human vasoactive intestinal peptide (VIP) molecules. Free energy calculations reveal that molecules of the poorly water-soluble drug bexarotene can reside at the micellar ionic interface of the PEG corona, with their polar ends pointing out. Alternatively, they can reside in the alkane core center, where several bexarotene molecules can self-stabilize by forming a cluster held together by a network of hydrogen bonds. We also show that highly charged molecules, such as VIP, can be stabilized at the SSM ionic interface by Coulombic coupling between their positively charged residues and the negatively charged phosphate headgroups of the lipids. The obtained results illustrate that atomistic simulations can reveal drug solubilization character in nanocarriers and be used in efficient optimization of novel nanomedicines.



INTRODUCTION

Many therapeutic molecules exhibit a limited aqueous solubility, a reduced *in vivo* stability, and major side effects due to nonspecific delivery.^{1,2} These limitations can be addressed in modern nanomedicines, where drug molecules are encapsulated within various nanocarriers.^{3–6} In particular, lipid-based micellar nanocarriers can solubilize hydrophobic drugs with high loading capacity, protect them from degradation, improve their availability at disease sites, and suppress their side activity.⁷

Today's predictive strategies anticipate the drug solubility in lipid nanocarriers from their bulk partition coefficients (water/octanol).^{8–10} These indirect strategies fail to provide the information on the exact location of the drugs within the nanocarrier. However, the drug location in a nanocarrier can determine its stability, protection, loading efficiency, and release rate, which are all crucial for the therapeutic effects of the drug.^{11,12} Drugs that are buried in the nanocarrier interior and more strongly attached to it tend to be more stable and better protected against degradation and inactivation.⁷ The number of drug molecules that can be loaded in a nanocarrier is determined by the effective volume of their preferred location. The release rate (transport) of a drug from the nanocarrier is determined by its solvation free energy and local diffusion constants in the carrier.¹³ In order to develop new nanomedicines and optimize their pharmaceutical properties and physiological effects, we need to understand the stabilization mechanisms of therapeutic agents within the nanocarriers.⁸

In principle, the drug–nanocarrier complexation could be described by precise atomistic simulations. In the past, a typical use of molecular dynamics (MD) simulations was to predict free energies of solvation for short alkanes in the cores of small surfactant micelles¹⁴ or the permeation of small solutes through lipid membranes.^{15,16} In our recent large-scale atomistic MD simulations, phospholipid-based sterically stabilized micelles (SSM) were explored in water and saline solutions.¹⁷ In Figure 1b–d, we show atomistic models of SSM in pure water and aqueous solutions of different ionic strength. Our previous experiments have shown that such SSM can solubilize different hydrophobic and amphiphilic drug molecules^{18,19} and peptides.^{20–24} However, the stabilization mechanisms and the exact location and organization of these drugs within SSM are not known.

In this work we use precise atomistic MD simulations combined with free energy calculations to model the stabilization of a small water-insoluble drug bexarotene (BEX) and a human vasoactive intestinal peptide (VIP) inside SSM, as observed in our experiments. The aim of the simulations is to identify the equilibrated locations and binding energies of the drug molecules within the SSM nanocarriers (Figure 1b–d).

Received: May 31, 2013

Published: November 27, 2013




Figure 1. (a) DSPE-PEG₂₀₀₀ monomer with Na⁺ counterion. (b) Equilibrated SSM-10 in water. The characteristic layers in this system are alkane core ($r_{\text{core}} \approx 0\text{--}1.2$ nm, shown as a gold surface), ionic interface ($r_{\text{int}} \approx 1.2\text{--}1.8$ nm; the negatively charged PO₄⁻ groups are shown as black and orange clusters), PEG corona ($r_{\text{PEG}} \approx 1.8\text{--}3.0$ nm, shown as turquoise and red chains), and aqueous ionic solution ($r_{\text{aq}} > 3.0$ nm, not shown for clarity). (c) Equilibrated SSM-20 in water, modeled after the SSM observed by DLS experiments in PB buffer (low ionic strength solution), with $r_{\text{core}} \approx 0\text{--}1.7$ nm, $r_{\text{int}} \approx 1.7\text{--}2.3$ nm, $r_{\text{PEG}} \approx 2.3\text{--}3.8$ nm, and $r_{\text{aq}} > 3.8$ nm. (d) Equilibrated SSM-90 in 0.16 M NaCl solution, with $r_{\text{core}} \approx 0\text{--}2.4$ nm (along minor axis), $r_{\text{int}} \approx 2.4\text{--}3.0$ nm, $r_{\text{PEG}} \approx 3.0\text{--}7.5$ nm, and $r_{\text{aq}} > 7.5$ nm. In SSM shown in (c, d), PO₄⁻ groups and PEG chains are removed for clarity on the left sides of the images.

MATERIALS AND METHODS

Experimental Characterization of SSM. Blank and bexarotene-containing SSM nanocarriers (SSM-BEX) were prepared in HEPES buffer from PEG-ylated phospholipid 1,2-distearoyl-*sn*-glycero-3-phosphatidylethanolamine-*N*-[methoxy(polyethylene glycol)-2000] sodium salt (DSPE-PEG₂₀₀₀). Several solutions with the bexarotene concentration in the range of 0–60 μg/mL and 1 mM DSPE-PEG₂₀₀₀ concentration were prepared by the film-rehydration method, described extensively in refs 5 and 19. These solutions were tested to determine the maximum solubilization capacity of SSM for bexarotene. Micelle dispersions were analyzed by dynamic light scattering (DLS) for the particle distributions and by HPLC for the drug content.

The VIP-SSM complexes were prepared in standard phosphate buffered saline (PBS, pH = 7.4) and phosphate buffer solutions (PB, 1 mM, pH = 7.4). The prepared solutions had constant VIP concentration $c_{\text{VIP}} = 4.0$ μM and variable DSPE-PEG₂₀₀₀ concentration in the range $c_{\text{lip}} = 0\text{--}0.4$ mM. The VIP-SSM assemblies were characterized by DLS and fluorescence spectroscopy. Intrinsic fluorescence of tyrosine residues in VIP was used (the excitation wavelength $\lambda_{\text{ex}} = 277$ nm, the emission wavelength $\lambda_{\text{em}} = 304$ nm). Materials, methods, and our experimental procedures are described in detail in the Supporting Information.

MD Simulations. In Figures 1a, 1b, 1c, and 1d we show a single DSPE-PEG₂₀₀₀ monomer, the free SSM-10 (SSM with the aggregation number $N_{\text{agg}} = 10$, modeled in water), SSM-20 ($N_{\text{agg}} = 20$, water), and SSM-90 ($N_{\text{agg}} = 90$, 0.16 M NaCl), respectively. The free and drug-filled micelles were modeled by atomistic classical MD simulations using the NAMD package²⁵ and CHARMM force field (CHARMM27 and C3Sr revision for ethers, TIP3P water model).^{26,27} The prepared free SSMs were equilibrated for 5–10 ns in the NpT ensemble at $p = 1$ bar and $T = 300$ K, and the electrostatics were evaluated with the PME method.²⁸

In the BEX-SSM simulations, we used SSM-10 (Figure 1b) and SSM-90 (Figure 1d). The choice of SSM-10 is based on the comparison of SSM sizes in water obtained by DLS measurements

and our previous MD simulations;¹⁷ the comparison was validated by showing that the diameters of simulated SSM were in agreement with diameters of SSM in buffer obtained from DLS measurements. The SSM-90 in buffer is based on the SANS measurements of SSM in 10 mM HEPES buffered saline (pH = 7.4) at the $c_{\text{lip}} = 5$ mM lipid concentration.^{29,30} The ionic strength of the simulated NaCl solution matches the ionic strength of the experimental buffer solution. Since SANS measurements showed that SSM-90 is nearly spherical (slightly oblate),²⁹ DSPE-PEG₂₀₀₀ monomers were initially spherically distributed in all the simulations of empty SSMs. SSM-10 in water remained spherical in all equilibration and free energy simulations. SSM-90 became oblate during the first few nanoseconds of equilibration and remained oblate during the equilibration and multiple free energy simulations. We used the adaptive biasing force (ABF) method^{31–33} to calculate the solvation Gibbs free energy (ΔG) profiles of bexarotene inside SSM-10 and SSM-90. For comparison, we evaluated ΔG profiles of bexarotene at the interfaces of octane with aqueous solutions.

In the VIP-SSM simulations, we prepared the SSM-20 (Figure 1c) and SSM-90 (Figure 1d). The aggregation numbers ($N_{\text{agg}} = 20, 90$) were chosen to match the experimental SSM sizes observed in PB and PBS solutions. The SSM-20 was solvated in water; the ionic strength of the PB solution with the $\lambda_{\text{D}} = 9.7$ nm Debye length is so weak that there is a negligible number of ions in the simulation box. The SSM-90 was solvated in 0.16 M NaCl solution. The SSMs had VIP molecules placed in PEG palisade regions. In SSM-20, VIP was used in its molecular form, representing a therapeutic agent. In SSM-90, VIP was tethered to a DSPE-PEG₃₄₀₀ monomer as a targeting agent (tail end of the PEG chain), whose alkane chains were inserted into the SSM core. We equilibrated the VIP-SSM systems for $t \approx 30$ ns. Further information about the computational methods is given in the Supporting Information.

RESULTS AND DISCUSSION

Solubilization of Bexarotene in SSM. The SSM is formed by DSPE-PEG₂₀₀₀ copolymers, containing two acyl chains, a negatively charged phosphate group, and a long PEG chain, as shown in Figure 1a. First, we study experimentally bexarotene solubilization in SSM by dynamic light scattering. We find the maximum solubilization of bexarotene (without formation of precipitate) by monitoring its saturation concentration, c_{bex} in DLS experiments. After a certain number of drug molecules occupies (saturates) SSM, the drugs start to precipitate in the form of secondary particle species. The secondary particle species were previously investigated for other drugs by DLS and transmission electron microscopy (TEM).^{18,34} Here, we monitor the sizes of SSM and the secondary particle species by DLS only.

In Figure 2, we show the particle size distributions obtained by DLS for SSM dispersions ($c_{\text{lip}} = 1$ mM) containing bexarotene in HEPES buffered saline, as we vary the concentration of bexarotene, c_{bex} . The DLS measurements show similar SSM particle size distributions, $d_{\text{h}} \approx 15$ nm, for dispersions at the bexarotene concentration $c_{\text{bex}} \leq 50$ μg/mL. At $c_{\text{bex}} = 60$ μg/mL, in addition to the SSM diameter of $d_{\text{h}} \approx 15$ nm, particles with an average hydrodynamic diameter of $d_{\text{h}} \approx 500$ nm were also observed. Previous DLS and TEM experiments revealed particles of similar sizes in solutions of SSM and other drug molecules (camptothecin, paclitaxel); spherical SSM ($d_{\text{h}} \approx 15$ nm) were observed at low drug concentrations, while larger particles ($d_{\text{h}} \approx 300\text{--}500$ nm) appeared when drug concentrations exceeded the solubility limit in SSM.^{18,34}

Since the intrinsic solubility of bexarotene in HEPES buffered saline is 0.56 μg/mL (determined by HPLC), the data in Figure 2 indicate that the maximum solubility of




Figure 2. Experimental intensity-weighted particle size distributions obtained by DLS in HEPES buffered saline with the DSPE-PEG₂₀₀₀ concentration of $c_{lip} = 1$ mM and the bexarotene concentrations of $c_{bex} = 0, 50,$ and 60 $\mu\text{g/mL}$.

bexarotene in SSMs is $c_{bex} = 50\text{--}60$ $\mu\text{g/mL}$, at the DSPE-PEG₂₀₀₀ concentration of $c_{lip} = 1$ mM. On the basis of the intrinsic solubility of bexarotene in HEPES buffered saline and the fact that ≈ 90 lipid monomers form one micelle,²⁹ we determined that on average $N_{bex} \approx 11$ bexarotene molecules are encapsulated within SSM.

Simulations of SSM-BEX Nanomedicines. Since drugs can be solvated in different regions of the SSM interior (Figure 1), it is good to understand the structure of the SSM regions. The central (nonpolar) SSM core region is formed by densely aggregated alkane chains of various levels of interconnection and fluidity. The core is surrounded by covalently attached PO_4^- groups and their free hydrated Na^+ counterions, positioned at a certain distance from PO_4^- groups (depending on the ionic strength of the solution). The ionic interface (PO_4^- groups) is surrounded by the PEG corona, which is immersed in water (SSM-10) or 0.16 M NaCl solution (SSM-90). In the corona, the Na^+ counterions are often solvated in oxygen atom pockets formed by PEG chains.^{17,35} Density distributions in SSM, analyzed in ref 17, show that SSM regions change gradually along the radial coordinate r . On the other hand, radial distributions of ions in SSM show strong gradients around the ionic interface, observed at $1 \text{ nm} < r < 3 \text{ nm}$ for SSM-10 in water and at $1.8 \text{ nm} < r < 5 \text{ nm}$ for SSM-90 in 0.16 M NaCl.¹⁷ The micelle interior is heterogeneous and fluctuating. While in SSM-10, the ionic interface and the alkane core are highly exposed to water; in SSM-90, PEG forms a relatively homogeneous layer, which can spread and expose the SSM core to the bulk aqueous solution.¹⁷

Solvation of Bexarotene at the SSM-Core Interface. First, we examine the possibility of solvation of bexarotene at the hydrophobic/philic SSM-core interface, which might be a less favorable place of residence for drugs that are poorly soluble in water.⁷ In Figure 3a, we show the Gibbs free energy profiles, $\Delta G(r)$, for a single bexarotene molecule along the radial coordinate r in SSM-10 and SSM-90. In SSM-10, $\Delta G(r)$ has a single minimum, while in SSM-90 two minima of different depths are observed. In both SSMs, the global minimum forms in a region located between the alkane cores and the ionic interfaces, at $r \approx 0.8\text{--}1.2$ nm (SSM-10) and $r \approx 1.7\text{--}2.5$ nm (SSM-90). The barriers for transfer of bexarotene from these




Figure 3. (a) Free energy profiles of bexarotene in SSM-10 (water) and SSM-90 (0.16 M NaCl). Whole solvated micelles loaded with drugs were present in the free energy calculations; different numbers of drugs are considered in the SSM-90 core. The vertical arrows show the positions of ionic interfaces in the two SSMs. (b) Free energy profiles of bexarotene across the interfaces of octane with pure water, 0.16 M NaCl, and hydrated PEG. Interfaces in these planar systems are located at $r \approx 2.5$ nm (red arrow). The free energy in a hydrated octane nanodroplet of the radius 2.1 nm is also shown. The interface in this system is marked by the blue arrow.

minima into the alkane cores of both SSMs are $\Delta\Delta G(r) \approx 4$ kcal/mol, whereas the barriers for transfer into the aqueous PEG regions are $\Delta\Delta G(r) \approx 10$ kcal/mol. In these interfacial minima, bexarotene has its polar $-\text{COOH}$ group oriented toward the aqueous region, while its body is immersed in the alkane region (Figure 4c).

The results in Figure 3a can be compared with $\Delta G(r)$ profiles for bexarotene at flat interfaces of two bulk liquids with properties similar to the SSM regions. However, note that flat interfacial systems contain only some of the elements which contribute to the complexity of the SSM environment (curvature, strong gradients in ion concentration¹⁷). In Figure 3b, we show $\Delta G(r)$ at octane interfaced with pure water, 0.16 M NaCl solution, and $\approx 70\%$ w/w hydrated PEG. The curves are aligned in the regions of the same solvent and geometry (bulk). In all the cases, bexarotene has energy minima at the




Figure 4. (a) A snapshot of the cluster of 5 beaxarotene molecules formed inside the SSM core, after 11 ns of equilibration. A hydrogen bond network between $-\text{COOH}$ groups is highlighted. (b) The cluster of 11 beaxarotene molecules forms 2 hydrogen bond networks in the SSM core after 17 ns of equilibration (transparent background shows the whole 11-drug cluster, and the atoms shown in the stick representation participate in the H-bond network). (c) A solvated beaxarotene molecule orients its nonpolar part to the alkane core and its $-\text{COOH}$ group toward the ionic interface (shown in SSM-90).

interfaces. In aqueous solutions, the minima are shifted toward octane and the barriers are asymmetrical, as in SSM in Figure 3a, with $\Delta\Delta G(r) \approx 12.5$ kcal/mol on the aqueous side and $\Delta\Delta G(r) \approx 4.5$ kcal/mol on the octane side. The barrier for beaxarotene transfer into 70% w/w PEG in water is significantly reduced, $\Delta\Delta G(r) \approx 5$ kcal/mol. However, since PEG in SSM has a smaller density than in Figure 3b ($\approx 25\text{--}50\%$ w/w for $r = 3\text{--}4$ nm in SSM-90¹⁷), the barrier reduction in SSM-10 and SSM-90 was not observed.

It is also of interest to consider the intermediate case between the flat alkane–water interface and the SSM. In Figure 3b, we show the free energy profile for beaxarotene solvated in a hydrated octane nanodroplet with a radius of $r = 2.1$ nm. Here, the energy curves are aligned in the bulk water solvent. The data reveal an increase of $\Delta G(r) \approx 5$ kcal/mol in the core beyond the value observed in the bulk octane. This Gibbs energy growth inside octane nanodroplets can be attributed to the Laplace pressure (surface tension),³⁶ which is largely reduced in SSM formed by the amphiphilic monomers. To our knowledge, this Laplace pressure effect was not quantified in nanodroplets with a molecular structure.

Solvation of Beaxarotene in the SSM Core. Next, we discuss beaxarotene solvation in the SSM core, which is considered in micellar nanomedicines as the dominant residing region for

poorly water-soluble drug molecules.⁷ Figure 3a shows that a single beaxarotene already has a shallow minimum in the SSM-90 core, which is not seen in SSM-10 (no significant bulk region exist within $r < 1.0$ nm) and the bulk systems. Even though this minimum in the SSM-90 core is shallower than at the core interface, potential cooperative effects between multiple drugs present in the core might increase the chance for the drugs to stay there.

In our previous simulations,¹⁷ we observed that a cavity with diameter $d \approx 1$ nm, present initially in the SSM-90 core, disappeared after the first 1–2 ns of simulations. The core became oblate as the cavity closed up and the alkane tail ends formed an interface-like region. The cavity has the potential to host drug molecules, since the molecular solvation free energies can be reduced over there. The core center is analogous to the middle of a lipid bilayer, where the energy required to form a cavity is decreased, due to the lower density of the alkane tails.¹⁵ This energy reduction could potentially explain the local minimum in $\Delta G(r)$ seen to form for a single beaxarotene in the SSM-90 core (Figure 3a). To further investigate the capacity of the cavity to host drugs, we try to accommodate 3 and 5 beaxarotene molecules in the initial cavity within the SSM-90 core. Although these drug numbers might be realistic, due to relatively large steric forces within the SSM-90 core, we still


need to examine if 11 bexarotene molecules observed in the experimental micelles ($N_{\text{bex}} = 11$) are likely to occupy the SSM core as a cluster.

During the equilibration of systems with multiple drugs, the cavity in the SSM core partially collapses and the drugs reorient into a configuration with inward pointing $-\text{COOH}$ groups, thus forming a molecular cluster held together by a hydrogen bond network (analogue of a small inverse micelle). In Figure 4a, we show the arrangement of 5 bexarotene molecules and the hydrogen bond network formed by them within the alkyl core, after $t \approx 11$ ns of equilibration. To examine if bexarotene prefers to remain within the cluster of drug molecules formed in the SSM core rather than at its ionic interface, we calculate $\Delta G(r)$ for one of these bexarotene molecules as a function of its distance from the SSM center (drug cluster). In Figure 3a, we show that $\Delta G(r)$ develops a deeper minimum in the core center in the presence of multiple bexarotene molecules. Its depth increases with the number of drugs present in the core, and for 5 drugs it surpasses the local minimum at the ionic interface. The developed minima in the core can explain the large loading capacity of SSM-90.

Next, we briefly examine whether all the observed ($N_{\text{bex}} \approx 11$) bexarotene molecules can possibly fit in the SSM-90 core. In Figure 4b, we show 11 bexarotene molecules equilibrated for $t \approx 17$ ns in the SSM-90 core. Nine molecules formed one H-bond network (not anymore a ring), while the remaining two molecules separated from this cluster when their $-\text{COOH}$ groups associate with each other. The formation of two hydrogen bond centers indicates potential crowding in the SSM-90 core in the presence of 11 bexarotene molecules. Therefore, the 11 bexarotene drugs are potentially located both in the core and at the ionic interface of SSM-90, where the local minima in free energy are seen to form.

Solubilization of VIP in SSM. In the next example of nanomedicine modeling, we study the solubilization of VIP in SSM. The stabilization of VIP-SSM complexes is based on different principles, since the VIP peptide is chemically very different from bexarotene. Fluorescence measurements of VIP tyrosine residues were used to find the average number of VIP molecules solubilized in SSM in PB and PBS solutions containing DSPE-PEG₂₀₀₀ lipids ($c_{\text{lip}} = 0\text{--}0.4$ mM). In the absence of DSPE-PEG₂₀₀₀, the fluorescence of hydrated VIP molecules is quenched due to their aggregation.³⁷ On the other hand, when VIP is associated with SSM in its monomeric form, its fluorescence can be observed (increased from its background value). We increased the ratio of DSPE-PEG₂₀₀₀ to VIP in PB and PBS solutions of a constant VIP concentration ($c_{\text{VIP}} = 4$ μM) by changing the DSPE-PEG₂₀₀₀ concentration and tracked the ratio at which the VIP fluorescence saturated. When this occurred, all the present VIP should have been complexed with SSM, assuming that no aggregated VIP molecules were in the solutions.

In Figure 5 (top), we show the ratiometric intensity curves of the PB and PBS solutions containing DSPE-PEG₂₀₀₀ (varying concentration) and VIP ($c_{\text{VIP}} = 4$ μM). The results show that there are ≈ 10 and ≈ 14 DSPE-PEG₂₀₀₀ monomers per each VIP in the PB and PBS solutions, respectively. In the table in Figure 5 (bottom), we present the DLS hydrodynamic diameters of SSM (d_h) in PB and PBS solutions and inferred SSM aggregation numbers, N_{agg} (according to the estimate method validated in ref 17). The data indicate that SSM in PB solutions have $N_{\text{agg}} \approx 20$ (Figure 1b) and can complex with ≈ 2 VIP molecules, whereas SSM in PBS solutions have $N_{\text{agg}} \approx 90$



Solvent	$N_{\text{mon}}:N_{\text{VIP}}$	d_h [nm]	N_{agg}	$N_{\text{VIP}}:N_{\text{SSM}}$
PBS	14:1	13.7 ± 0.7	90	6:1
PB	10:1	8.2 ± 1.3	20	2:1

Figure 5. (top) Normalized VIP fluorescence intensity, I/I_0 , as a function of the $c_{\text{lip}}/c_{\text{VIP}}$ ratio, where I and I_0 are fluorescence intensities observed for VIP in solutions with and without DSPE-PEG₂₀₀₀ monomers, respectively. A steady-state approximation (arrows) is used to obtain the $N_{\text{mon}}:N_{\text{VIP}}$ saturation molar ratio, shown in the table (bottom). The VIP concentration is $c_{\text{VIP}} = 4$ μM , while the concentration of DSPE-PEG₂₀₀₀ is varied. The table also shows d_h ,¹⁷ determined by DLS, and estimated SSM aggregation numbers, N_{agg} ,¹⁷ which are used to determine the VIP loading efficiency ($N_{\text{eff}} = N_{\text{VIP}}/N_{\text{SSM}}$).

(Figure 1c) and can complex with ≈ 6 VIP molecules. The finding that SSM in PBS are significantly larger than those in PB solution is in agreement with our previous finding that SSM size increases with the ionic strength of the solvent.¹⁷

Simulations of VIP-SSM Nanomedicines. The experimental results shown in Figure 5 indicate that individual SSMs in PB and PBS solutions can stabilize several VIP molecules. In order to reveal the interaction mechanisms leading to VIP stabilization, we simulate the VIP-SSM complexes in solvents of low (water) and high (0.16 M NaCl) ionic strengths. Our model of the VIP peptide has a net +3 charge, with 2 clusters of positively charged residues (Arg-Leu-Arg-Lys and Lys-Lys), two well-separated negatively charged residues (two Asp), and the charged C and N termini. While in this work, VIP is stabilized within the SSM in its free form, in our previous experiments, the incorporated VIP was conjugated to a DSPE-PEG₃₄₀₀ into the SSM.³⁸ To examine the two representative experimental systems, we simulate binding of the free VIP to SSM-20 (in low ionic strength solvent) and binding of the conjugated VIP to SSM-90 (in high ionic strength solvent).

Complexation of VIP with SSM-20. First, we model the complexation of 2 VIP molecules with SSM-20 in water, based on the experimental data for the PB buffer (low ionic strength), shown in Figure 5. Initially, the two VIP molecules are placed on the opposite sides of SSM-20, within 0.7 nm of its core edge, and the whole system is equilibrated for $t \approx 30$ ns. After the first ≈ 10 ns, both VIP molecules become closely coordinated to




Figure 6. (a) MD snapshots of VIP-1 and VIP-2 complexed on the opposite sides of SSM-20 (inset (d)). The alkyl core, shown as a yellow surface (PEG corona not shown for clarity), is surrounded by PO₄⁻ groups (black, orange), which coordinate with two positively charged regions on each of the VIP peptides. VIP molecules are shown as green ribbons; the residues of the positively charged regions are shown in atomic detail. The VIP molecule used in experiments has an aminated His end and an amidated Asn end. In our modeling, the His and Asn ends were C- and N-termini, respectively. (b) SSM-90 core complexed with DSPE-PEG₃₄₀₀-conjugated VIP viewed from the side and from the top. The PEG₃₄₀₀ chain is shown in teal (C atoms) and red (O atoms) colors. (c) VIP sequence. Neutral, negatively charged, and positively charged residues are marked in light green, red, and blue, respectively. (d) Average number N of PO₄⁻ groups at the distance r from each positively charged VIP-1 and VIP-2 residues (center of mass of the atoms carrying the charge) for SSM-20. The averaging is performed over the last 17 ns of the 30 ns simulations. (e) The same as in (d) for SSM-90. The averaging is performed over the last 7 ns of the 30 ns simulation. (inset) Details of Arg and Lys coordination to the PO₄⁻ groups (VIP on the side of the SSM).

the PO₄⁻ groups positioned at the surface of the alkane core, as shown in Figure 6a. The PO₄⁻ groups migrate primarily toward the two clusters of positively charged residues and then redistribute more homogeneously on the alkane core surface. The coordination of PO₄⁻ groups with the positive residues occurs due to their strong Coulombic coupling, which is poorly screened in water (Debye length in 1 mM PB solution is $\lambda_D \approx 9.7$ nm).

In Figure 6d, we show the average number of PO₄⁻ groups at the distance r from the positive residues of VIP, calculated in VMD.³⁹ These results reveal that among the 5 positive residues on each VIP, there are at least 3 of them which are almost fully coordinated by counterions (≈ 1 PO₄⁻ group within $r = 0.7$ nm of the residue center of mass). The fact that VIP remains in the proximity of the SSM interface during the simulations suggests that Coulombic coupling is the primary VIP-SSM stabilization mechanism.

Complexation of VIP with SSM-90. Besides being a highly potent drug nanocarrier, SSM can also serve as a base for targeting agents. Such targeting can be achieved by grafting the distal end of the PEG moiety of the phospholipid with VIP.³⁸ Here, we model VIP complexation with SSM-90 in a 0.16 M NaCl solution, where VIP is conjugated to the tail end of the PEG chain on one DSPE-PEG₃₄₀₀ monomer (up to 5 VIP molecules conjugated to the distal end of a PEG-ylated lipid

could complex with one micelle³⁸). The long PEG chain allows easy accommodation of VIP in the SSM environment. Since the SSM-90 core is oblate,¹⁷ we separately model VIP loading along its major (top) and minor (side) axes. The VIP segment of the conjugated monomer is initially placed within 0.7 nm of the micelle core edge, and the system is equilibrated for ≈ 30 ns.

During the equilibration of both VIP orientations in SSM-90, the micelle core rearranges to better coordinate with VIP. After the initial readjustment, the PO₄⁻ groups redistribute more homogeneously and reshape the micelle, as seen in Figure 6b. In the side binding, the core slightly elongates along the major SSM axis. In the top binding, the core stretches along its minor axis and becomes more spherical.

In SSM-90, the VIP is again tightly coordinated by the PO₄⁻ groups on the surface of the alkane core, despite a higher ionic strength and a more sterically protected environment. In Figure 6e, we show the average number of PO₄⁻ groups at the distance r from each positively charged VIP residue. Again, most of the VIP residues are surrounded (screened) by the PO₄⁻ groups at a short distance ($r < 1$ nm), where the top configuration seems to better accommodate VIP positive residues to the PO₄⁻ groups. Note that the coupling ratio of several positive residues and the PO₄⁻ groups is not 1:1, but there are pockets of several PO₄⁻ groups coordinating and stabilizing the residues (inset of Figure 6e, showing VIP stabilized on the side of the SSM-90

core). The large attraction and favorable coordination ratio maintain the VIP position at the ionic interface within the PEG corona. Note that VIP folding within SSM was also experimentally observed.^{20,38} Unfortunately, modeling of VIP folding is currently beyond our simulation times. However, it is very likely that the large negatively charged interfacial area of the SSM will play a significant role in stabilizing the oppositely charged VIP, even if partially folded.

CONCLUSION

In summary, we examined the solvation of two representative therapeutic molecules, bexarotene and VIP, in PEG-ylated phospholipid SSM nanocarriers. Experimentally, we found that ≈ 11 bexarotene drug molecules are solvated in SSM in HEPES buffered saline, while ≈ 2 and ≈ 6 VIP molecules are solvated in SSMs in the PB and PBS buffers, respectively. Our large-scale atomistic MD simulations and free energy calculations of the BEX-SSM complexes revealed that a single bexarotene molecule preferentially solvates at the ionic interface regions of SSM-10 and SSM-90. Even though a single bexarotene molecule is less stable in the SSM-90 core than at its ionic/alkane interface, we found that the core center can potentially host multiple bexarotene molecules which can help to stabilize each other. We also found that the VIP-SSM stabilization originates in close coordination of VIP positive residues with negatively charged PO_4^- groups capping the micelle core.

The observed stabilization of bexarotene and VIP in the SSM nanocarriers relies on the compatibility of the drug with the polymer building blocks of the SSM. Our simulations have shown that both hydrophobic and Coulombic interactions between the drug molecules and the phospholipid polymers can stabilize the drug molecules in the SSM. Tuning these and other interactions between the drug and the polymer blocks of the nanocarrier can be used to localize the drug in a specific region of the nanocarrier. Our studies clearly illustrate that precise atomistic simulations can bring essential understanding of drug–nanocarrier complexes, which can impact the discovery of future nanomedicines.

ASSOCIATED CONTENT

Supporting Information

Materials, experimental methods, partial atomic charges of bexarotene, computational methods. This material is available free of charge via the Internet at <http://pubs.acs.org>.

AUTHOR INFORMATION

Corresponding Authors

*E-mail: pkral@uic.edu (P.K.).

*E-mail: hayat@uic.edu (H.O.).

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This study was supported in part by grants from the National Institutes of Health (R01AG024026, R01CA12797). We acknowledge the support from the UIC Dean Scholar Award (L.V.), UIC College of Pharmacy Van Doren Scholarship (A.B.), and UIC Herbert E. Paaren Summer and Academic Year Research Scholarships (A.M. and A.T.). The simulations were partly performed at the NERSC, NCSA, and BlueGene (ANL) supercomputers as well as local GPU servers.

REFERENCES

- (1) Brayden, D. J. Controlled release technologies for drug delivery. *Drug Discovery Today* **2003**, *8*, 976–978.
- (2) Neslihan Gursoy, R.; Benita, S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. *Biomed. Pharmacother.* **2004**, *58*, 173–182.
- (3) Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. *Nat. Nanotechnol.* **2007**, *2*, 751–760.
- (4) Duncan, R. The dawning era of polymer. *Nat. Rev. Drug Discovery* **2003**, *2*, 347.
- (5) Koo, O. M.; Rubinstein, I.; Onyuksel, H. Role of nanotechnology in targeted drug delivery and imaging: a concise review. *Nanomedicine* **2005**, *1*, 193–212.
- (6) Torchilin, V. Micellar nanocarriers: Pharmaceutical perspectives. *Pharm. Res.* **2007**, *24*, 1–16.
- (7) Lim, S. B.; Banerjee, A.; Önyüksel, H. Improvement of drug safety by the use of lipid-based nanocarriers. *J. Controlled Release* **2012**, *163*, 34–45.
- (8) Rane, S. S.; Anderson, B. D. What determines drug solubility in lipid vehicles: Is it predictable? *Adv. Drug Delivery Rev.* **2008**, *60*, 638–656.
- (9) Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv. Drug Delivery Rev.* **2001**, *46*, 3–26.
- (10) Avdeef, A.; Testa, B. Physicochemical profiling in drug research: a brief survey of the state-of-the-art of experimental techniques. *Cell. Mol. Life Sci.* **2002**, *59*, 1681–1689.
- (11) Torchilin, V. P. Structure and design of polymeric surfactant-based drug delivery systems. *J. Controlled Release* **2001**, *73*, 137–172.
- (12) Allen, C.; Maysinger, D.; Eisenberg, A. Nano-engineering block copolymer aggregates for drug delivery. *Colloids Surf., B* **1999**, *16*, 3–27.
- (13) Xiang, T.-X.; Anderson, B. D. Liposomal drug transport: A molecular perspective from molecular dynamics simulations in lipid bilayers. *Adv. Drug Delivery Rev.* **2006**, *58*, 1357–1378.
- (14) Yoshii, N.; Iwahashi, K.; Okazaki, S. A molecular dynamics study of free energy of micelle formation for sodium dodecyl sulfate in water and its size distribution. *J. Chem. Phys.* **2006**, *124*, 184901–6.
- (15) Marrink, S.-J.; Berendsen, H. J. C. Simulation of water transport through a lipid membrane. *J. Phys. Chem.* **1994**, *98*, 4155–4168.
- (16) Bemporad, D.; Luttmann, C.; Essex, J. Behaviour of small solutes and large drugs in a lipid bilayer from computer simulations. *Biochim. Biophys. Acta, Biomembr.* **2005**, *1718*, 1–21.
- (17) Vuković, L.; Khatib, F. A.; Drake, S. P.; Madriaga, A.; Brandenburg, K. S.; Král, P.; Onyuksel, H. Structure and dynamics of highly PEG-ylated sterically stabilized micelles in aqueous media. *J. Am. Chem. Soc.* **2011**, *133*, 13481–13488.
- (18) Koo, O. M.; Rubinstein, I.; Onyuksel, H. Camptothecin in sterically stabilized phospholipid micelles: A novel nanomedicine. *Nanomedicine* **2005**, *1*, 77–84.
- (19) Onyuksel, H.; Mohanty, P. S.; Rubinstein, I. VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin: A novel targeted nanomedicine for breast cancer. *Int. J. Pharm.* **2009**, *365*, 157–161.
- (20) Sethi, V.; Rubinstein, I.; Kuzmis, A.; Kastrissios, H.; Artwohl, J.; Onyuksel, H. Novel, biocompatible, and disease modifying VIP nanomedicine for rheumatoid arthritis. *Mol. Pharmacol.* **2013**, *10*, 728–738.
- (21) Kuzmis, A.; Lim, S. B.; Desai, E.; Jeon, E.; Lee, B.-S.; Rubinstein, I.; Önyüksel, H. Micellar nanomedicine of human neuropeptide Y. *Nanomedicine* **2011**, *7*, 464–471.
- (22) Lim, S.; Rubinstein, I.; Sadikot, R.; Artwohl, J.; Önyüksel, H. A Novel peptide nanomedicine against acute lung injury: GLP-1 in phospholipid micelles. *Pharm. Res.* **2011**, *28*, 662–672.
- (23) Banerjee, A.; Onyuksel, H. Human pancreatic polypeptide in a phospholipid-based micellar formulation. *Pharm. Res.* **2012**, *29*, 1698–1711.

- (24) Banerjee, A.; Onyuksel, H. Peptide delivery using phospholipid micelles. *WIREs Nanomed. Nanobiotechnol.* **2012**, *4*, 562–574.
- (25) Phillips, J. C.; Braun, R.; Wang, W.; Gumbart, J.; Tajkhorshid, E.; Villa, E.; Chipot, C.; Skeel, R. D.; Kale, L.; Schulten, K. Scalable molecular dynamics with NAMD. *J. Comput. Chem.* **2005**, *26*, 1781–1802.
- (26) MacKerell, A. D.; Bashford, D.; Bellott, Dunbrack, R. L.; Evanseck, J. D.; Field, M. J.; Fischer, S.; Gao, J.; Guo, H.; Ha, S.; Joseph-McCarthy, D.; Kuchnir, L.; Kuczera, K.; Lau, F. T. K.; Mattos, C.; Michnick, S.; Ngo, T.; Nguyen, D. T.; Prodhom, B.; Reiher, W. E.; Roux, B.; Schlenkrich, M.; Smith, J. C.; Stote, R.; Straub, J.; Watanabe, M.; Wiorkiewicz-Kuczera, J.; Yin, D.; Karplus, M. All-atom empirical potential for molecular modeling and dynamics studies of proteins. *J. Phys. Chem. B* **1998**, *102*, 3586–3616.
- (27) Lee, H.; Venable, R. M.; MacKerell, A. D., Jr.; Pastor, R. W. Molecular dynamics studies of polyethylene oxide and polyethylene glycol: Hydrodynamic radius and shape anisotropy. *Biophys. J.* **2008**, *95*, 1590–1599.
- (28) Darden, T.; York, D.; Pedersen, L. Particle mesh Ewald: An $N \cdot \log(N)$ method for Ewald sums in large systems. *J. Chem. Phys.* **1993**, *98*, 10089–10092.
- (29) Ashok, B.; Arleth, L.; Hjelm, R. P.; Rubinstein, I.; Önyüksel, H. In vitro characterization of PEGylated phospholipid micelles for improved drug solubilization: Effects of PEG chain length and PC incorporation. *J. Pharm. Sci.* **2004**, *93*, 2476–2487.
- (30) Arleth, L.; Ashok, B.; Onyuksel, H.; Thiyagarajan, P.; Jacob, J.; Hjelm, R. P. Detailed structure of hairy mixed micelles formed by phosphatidylcholine and PEGylated phospholipids in aqueous media. *Langmuir* **2005**, *21*, 3279–3290.
- (31) Darve, E.; Pohorille, A. Calculating free energies using average force. *J. Chem. Phys.* **2001**, *115*, 9169–9183.
- (32) Darve, E.; Rodriguez-Gomez, D.; Pohorille, A. Adaptive biasing force method for scalar and vector free energy calculations. *J. Chem. Phys.* **2008**, *128*, 144120–13.
- (33) Henin, J.; Chipot, C. Overcoming free energy barriers using unconstrained molecular dynamics simulations. *J. Chem. Phys.* **2004**, *121*, 2904–2914.
- (34) Krishnadas, A.; Rubinstein, I.; Onyuksel, H. Sterically stabilized phospholipid mixed micelles: in vitro evaluation as a novel carrier for water-insoluble drugs. *Pharm. Res.* **2003**, *20*, 297–302.
- (35) Pearson, R. M.; Patra, N.; Hsu, H.-j.; Uddin, S.; Král, P.; Hong, S. Positively charged dendron micelles display negligible cellular interactions. *ACS Macro Lett.* **2012**, *2*, 77–81.
- (36) Menger, F. M. Laplace pressure inside micelles. *J. Phys. Chem.* **1979**, *83*, 893–893.
- (37) Önyüksel, H.; Bodalia, B.; Sethi, V.; Dagar, S.; Rubinstein, I. Surface-active properties of vasoactive intestinal peptide. *Peptides* **2000**, *21*, 419–423.
- (38) Dagar, A.; Kuzmis, A.; Rubinstein, I.; Sekosan, M.; Onyuksel, H. VIP-targeted cytotoxic nanomedicine for breast cancer. *Drug Delivery Transl. Res.* **2012**, *2*, 454–462.
- (39) Humphrey, W.; Dalke, A.; Schulten, K. VMD: visual molecular dynamics. *J. Mol. Graphics* **1996**, *14*, 33–38.